Ribociclib plus letrozole in patients with hormone receptor‐positive, HER2‐negative advanced breast cancer with no prior endocrine therapy: subgroup analysis from the phase 3b CompLEEment‐1 trial: Subgroup analysis of the CompLEEment‐1 trial. Radiol Oncol [Internet]. 2022 Jul. 3 [cited 2026 Sep. 21];56(2):238-47. Available from: https://radioloncol.com/index.php/ro/article/view/3866